Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031135 | 0.80 | LMNA (0.48) | KDM4EGAAGDALMNADYRK1A | |
| SCHEMBL24660343 | 0.78 | SMN1; SMN2 (0.47) | KDM4EGAALMNADYRK1AADORA3 | |
| SCHEMBL30340827 | 0.78 | SMN1; SMN2 (0.47) | KDM4EGAALMNADYRK1AADORA3 | |
| SCHEMBL4526335 | 0.74 | GAK (0.48) | KDM4EGAADYRK1AMEN1TSHR | |
| SCHEMBL14895071 | 0.72 | DYRK1A (0.42) | KDM4EDYRK1AADORA3POLBALDH1A1 | |
| SCHEMBL22234866 | 0.72 | KDM4E (0.50) | KDM4ELMNADYRK1AALDH1A1 | |
| SCHEMBL21403508 | 0.71 | HCAR2 (0.36) | KDM4EDYRK1AMEN1KMT2AFGFR1 | |
| SCHEMBL2919354 | 0.71 | LMNA (0.63) | KDM4ELMNADYRK1AMEN1KMT2A | |
| SCHEMBL18109638 | 0.71 | DYRK1A (0.41) | KDM4EDYRK1AADORA3POLBALDH1A1 | |
| SCHEMBL859291 | 0.70 | DYRK1A (0.59) | DYRK1ASMN1; SMN2NPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566675-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250171443-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| CN-119613400-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12247026-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4212529-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-112135824-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4212529-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212529-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3774791-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3774791-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11124511-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3774791-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200255424-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-08-13 | — | — | US | disclosed |
| US-20200255424-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-08-13 | — | — | US | disclosed |
| US-10669271-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669271-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| WO-2019191707-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191707-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190300524-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-20190300524-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300524-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885GAA 2040/4885GDA 2377/4885 |
| US-10669271-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | KDM4E 3674/4885GAA 2040/4885GDA 2377/4885 |
| US-20200255424-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885GAA 2040/4885GDA 2377/4885 |
| US-11124511-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | KDM4E 3674/4885GAA 2040/4885GDA 2377/4885 |
| US-12247026-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | KDM4E 3674/4885GAA 2040/4885GDA 2377/4885 |
| US-20250171443-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885GAA 2040/4885GDA 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.